✦ LIBER ✦

PCN98 Health Outcome Gains and Costs Offset Associated With Everolimus for the Treatment of Hormone-Receptor–Positive (HR+) HER2-Negative (HER2–) Advanced Breast Cancer (ABC)

✍ Scribed by M. Taylor; L. Lewis; J. Vieira; J.F. Ricci; D. Chandiwana; S. Saletan; T. Sahmoud

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN59 Patterns of Clinical Management an

✍ F. Andre; N. Marinsek; J.F. Ricci; J. Etchberger; R. Degun; G. Benelli; S. Salet 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

An Indirect Treatment Comparison of the

✍ Chandiwana, D.; Vieira, J.; Granville, J.; McCool, R.; Fleetwood, K. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Comparison Between Everolimus (Afinitor®

✍ Vieira, J.; Chandiwana, D.; Taylor, M.; Lewis, L. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

NICE guidance on everolimus in combinati

✍ Burke, Martyn J; Garrett, Zoe; George, Elisabeth; Adler, Amanda I 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 53 KB

Everolimus in Combination with Exemestan

✍ Sohita Dhillon 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 426 KB

Costs of HER 2 Negative, Hormonal Recept

✍ Clark, O.A.C.; Paladini, L.; Engel, T.; Caldas, A.; Valentim, J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB